Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 1
1994 1
1995 1
1997 3
1998 3
1999 3
2000 1
2001 1
2002 3
2003 1
2004 3
2005 3
2006 1
2008 6
2009 5
2010 3
2011 5
2012 4
2013 4
2014 5
2015 6
2016 6
2017 7
2018 9
2019 8
2020 8
2021 11
2022 7
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Results by year

Filters applied: . Clear all
Page 1
Direct cardiac effects of SGLT2 inhibitors.
Chen S, Coronel R, Hollmann MW, Weber NC, Zuurbier CJ. Chen S, et al. Among authors: zuurbier cj. Cardiovasc Diabetol. 2022 Mar 18;21(1):45. doi: 10.1186/s12933-022-01480-1. Cardiovasc Diabetol. 2022. PMID: 35303888 Free PMC article. Review.
Cardiac metabolism as a driver and therapeutic target of myocardial infarction.
Zuurbier CJ, Bertrand L, Beauloye CR, Andreadou I, Ruiz-Meana M, Jespersen NR, Kula-Alwar D, Prag HA, Eric Botker H, Dambrova M, Montessuit C, Kaambre T, Liepinsh E, Brookes PS, Krieg T. Zuurbier CJ, et al. J Cell Mol Med. 2020 Jun;24(11):5937-5954. doi: 10.1111/jcmm.15180. Epub 2020 May 8. J Cell Mol Med. 2020. PMID: 32384583 Free PMC article. Review.
Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning.
Ferdinandy P, Andreadou I, Baxter GF, Bøtker HE, Davidson SM, Dobrev D, Gersh BJ, Heusch G, Lecour S, Ruiz-Meana M, Zuurbier CJ, Hausenloy DJ, Schulz R. Ferdinandy P, et al. Among authors: zuurbier cj. Pharmacol Rev. 2023 Jan;75(1):159-216. doi: 10.1124/pharmrev.121.000348. Epub 2022 Dec 8. Pharmacol Rev. 2023. PMID: 36753049 Free PMC article. Review.
Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2.
Chen S, Wang Q, Christodoulou A, Mylonas N, Bakker D, Nederlof R, Hollmann MW, Weber NC, Coronel R, Wakker V, Christoffels VM, Andreadou I, Zuurbier CJ. Chen S, et al. Among authors: zuurbier cj. Circulation. 2023 Jan 17;147(3):276-279. doi: 10.1161/CIRCULATIONAHA.122.061688. Epub 2023 Jan 17. Circulation. 2023. PMID: 36649392 No abstract available.
Targeting metabolic pathways to treat cardiovascular diseases.
Glatz JFC, Zuurbier CJ, Larsen TS. Glatz JFC, et al. Among authors: zuurbier cj. Biochim Biophys Acta Mol Basis Dis. 2020 Oct 1;1866(10):165879. doi: 10.1016/j.bbadis.2020.165879. Epub 2020 Jun 18. Biochim Biophys Acta Mol Basis Dis. 2020. PMID: 32562699 Free article. No abstract available.
NLRP3 Inflammasome in Cardioprotective Signaling.
Zuurbier CJ. Zuurbier CJ. J Cardiovasc Pharmacol. 2019 Oct;74(4):271-275. doi: 10.1097/FJC.0000000000000696. J Cardiovasc Pharmacol. 2019. PMID: 31356546 Review.
Mechanical ventilation of mice.
Schwarte LA, Zuurbier CJ, Ince C. Schwarte LA, et al. Among authors: zuurbier cj. Basic Res Cardiol. 2000 Dec;95(6):510-20. doi: 10.1007/s003950070029. Basic Res Cardiol. 2000. PMID: 11192374 Free PMC article. Review.
121 results